MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413497 | Name: Defoslimod

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Defoslimod is a cancer immmunotherapeutic agent

Chemical Structure

Defoslimod
Defoslimod
CAS#171092-39-0

Theoretical Analysis

MedKoo Cat#: 413497

Name: Defoslimod

CAS#: 171092-39-0

Chemical Formula: C53H102N2O20P2

Exact Mass: 1148.6501

Molecular Weight: 1149.34

Elemental Analysis: C, 55.39; H, 8.95; N, 2.44; O, 27.84; P, 5.39

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Defoslimod; OM174; OM-174; OM 174
IUPAC/Chemical Name
(R)-1-(((2R,3R,4R,5S,6R)-2-(((2R,3S,4R,5R,6R)-3,4-dihydroxy-5-((R)-3-hydroxytetradecanamido)-6-((phosphonooxy)methyl)tetrahydro-2H-pyran-2-yl)methoxy)-4-hydroxy-6-(hydroxymethyl)-5-(phosphonooxy)tetrahydro-2H-pyran-3-yl)amino)-1-oxotetradecan-3-yl dodecanoate
InChi Key
UUVVKHSZRKZOGM-CUECXTGJSA-N
InChi Code
InChI=1S/C53H102N2O20P2/c1-4-7-10-13-16-19-22-25-28-31-39(57)34-44(58)54-47-42(38-71-76(64,65)66)73-43(49(61)50(47)62)37-70-53-48(51(63)52(41(36-56)74-53)75-77(67,68)69)55-45(59)35-40(32-29-26-23-20-17-14-11-8-5-2)72-46(60)33-30-27-24-21-18-15-12-9-6-3/h39-43,47-53,56-57,61-63H,4-38H2,1-3H3,(H,54,58)(H,55,59)(H2,64,65,66)(H2,67,68,69)/t39-,40-,41-,42+,43-,47+,48-,49-,50-,51-,52-,53-/m1/s1
SMILES Code
CCCCCCCCCCC[C@H](CC(N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1COP(O)(O)=O)CO[C@@H]2O[C@@H]([C@H]([C@@H]([C@H]2NC(C[C@H](OC(CCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O)OP(O)(O)=O)CO)O)O)=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
To be determined 0.0 0.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,149.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol. 2007 Jun 1;563(1-3):1-17. doi: 10.1016/j.ejphar.2007.02.018. Epub 2007 Feb 17. PMID: 17383632. 2: Yu P, Cheng X, Guo J, Wang X. Toll-like receptors 2/4 agonists: a potential strategy for preventing invasion and metastasis of hepatocellular carcinoma. Gut. 2010 Oct;59(10):1447-8; author reply 1448-9. doi: 10.1136/gut.2009.190835. Epub 2010 Jul 30. PMID: 20675699. 3: Seignez C, Martin A, Rollet CE, Racoeur C, Scagliarini A, Jeannin JF, Bettaieb A, Paul C. Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils. Oncotarget. 2014 Nov 30;5(22):11442-51. doi: 10.18632/oncotarget.2556. PMID: 25347345; PMCID: PMC4294335. 4: Pajak B, Garze V, Davies G, Bauer J, Moser M, Chiavaroli C. The adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo. Vaccine. 2003 Feb 14;21(9-10):836-42. doi: 10.1016/s0264-410x(02)00529-7. PMID: 12547591. 5: D'Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol. 2005 Jul;5(7-8):1205-12. doi: 10.1016/j.intimp.2005.02.013. Epub 2005 Mar 19. PMID: 15914325. 6: Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M. Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172. doi: 10.1186/1471-2407-13-172. PMID: 23547558; PMCID: PMC3626800. 7: Larmonier CB, Arnould L, Larmonier N, Baumann S, Moutet M, Saint-Giorgio V, Pance A, Jeannin JF. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Int J Mol Med. 2004 Mar;13(3):355-61. PMID: 14767564. 8: Meraldi V, Audran R, Romero JF, Brossard V, Bauer J, López JA, Corradin G. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine. 2003 Jun 2;21(19-20):2485-91. doi: 10.1016/s0264-410x(03)00093-8. PMID: 12744882. 9: De Ridder M, Verovski VN, Chiavaroli C, Van den Berge DL, Monsaert C, Law K, Storme GA. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-gamma and inducible nitric oxide synthase. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1473-80. doi: 10.1016/j.ijrobp.2006.07.1381. Epub 2006 Oct 23. PMID: 17056198. 10: Onier N, Hilpert S, Arnould L, Saint-Giorgio V, Davies JG, Jeannin JF, Jeannin JF. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats. Clin Exp Metastasis. 1999 Jun;17(4):299-306. doi: 10.1023/a:1006663017149. PMID: 10545016.

View History

Emicerfont

Emicerfont

AUH-6-96

AUH-6-96

AU-8919

AU-8919

EMDT

EMDT